tirzepatide landmark trial for masld Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists Breaking Down MASLD vs. MASH

He completed his undergraduate and medical school degrees at Ohio State University, family medicine residency at Duke University, and sports medicine fellowship at the University of Florida

Nat Chem Biol (2020) 16(3):2409

When you eat less overall and drink insufficient water, stool becomes harder and moves more slowly through the colon

For the vast majority of patients, the immense, proven systemic benefits of GLP-1 medications, such as reversing severe obesity, stabilizing high blood sugar, reducing the risk of stroke, and preventing kidney failure, far outweigh this rare visual side effect

10.1186/s12866-022-02619-6 13

Congruence raises $32M for MC4R-deficient obesity program [3] [04 Sep 2025] Context: Financing from existing investors to advance CGX-926 and other programs discovered via the Revenir computational engine